Nutraceuticals

Targeting our second brain using prebiotics

Targeting our second brain using prebiotics

The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia remains a major target. For instance, we researched and demonstrated how the modulation of gut microbiota by prebiotics could permit the identification of novel enterosynes.

How does the gut microbiota interact with the your second brain?

How does the gut microbiota interact with the your second brain?

Currently, the gut is considered a primary site for the development of pathologies that modify brain functions such as neurodegenerative (Parkinson’s, Alzheimer’s, etc.) and metabolic (type 2 diabetes, obesity, etc.) disorders. Deciphering the mode of interaction between microbiota and the brain is a real original option to prevent (and maybe treat in the future) the establishment of gut-brain disfunctions and associated pathologies.

Camu camu and its applications in nutraceutics

Camu camu and its applications in nutraceutics

The Amazonian forests are home to a shrub, the camu-camu, whose fruit could be of great help in the fight against obesity and metabolic diseases. This is described in our latest study published with the A-Mansia R&D team in the journal Metabolites.

Targeting our second brain to fight diabetes

Targeting our second brain to fight diabetes

The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered a pioneering approach.

Research

Categorie

Archives

Enterosys will attend NutrEvent 2022 in Nantes

NutrEvent is the event dedicated to innovation in Food, Feed, Nutrition and Health. This year, NutrEvent is back for its 8th edition in hybrid format. Enterosys will be present with a validated, complete and innovative offer of in vitro and in vivo preclinical...

Enterosys welcomes its new business developer

Pauline Caseilles have joined the Enterosys team this month as Scientific Business Developer. Its aim is to publicize Enterosys' service offerings. Pauline obtained a Master’s degree in Health Biology and a Specialized Mastere in Marketing and Sales also in the field...

Antioxidant and anti-inflammatory properties of maternal milk

The high hydrostatic pressure processing of donor milk may better protect preterm infants from gut and liver pathologies compared to Holder pasteurization, which is currently used in most human milk banks. Preterm infants are highly susceptible to oxidative stress due...

Targeting our second brain using prebiotics

The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is an innovative approach. Among all the intestinal factors, the understanding of the role of gut microbes in controlling glycaemia remains a major target....

Commercial H/F – Biotechnologie

What we will accomplish together Pursue your career with a pure player in preclinical testing and accompany us in our growth! We need your scientific knowledge and your commercial appetite to build the commercial division! We are waiting for you at a key moment of our...